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Research
Studies conducted approximately a decade after 
the Chornobyl nuclear power plant accident 
among individuals exposed as children or ado-
lescents have demonstrated strong, consistent 
associations between radiation dose and risk 
of thyroid cancer with estimated odds ratios of 
approximately 5 at 1 Gy of exposure (Cardis 
et al. 2005; Davis et al. 2004; Ron 2007; 
Tronko et al. 2006a). The estimates of relative 
risk (RR) per gray from ecological studies are 
even higher (Jacob et al. 1999, 2006; Likhtarov 
et al. 2006). Ecological studies, however, are 
subject to limita  tions because of their use of 
grouped rather than individual doses and lim-
ited data on confounding factors (Lubin 2002). 
Although there has been substantial progress in 
quantifying iodine-131 (I-131)-related thyroid 
cancer risk, prospective incidence data from 
analytic epidemiological studies are lacking. 
Because thyroid cancers attributed to I-131 
exposure during childhood, similar to exter-
nal irradiation, continue to occur throughout 
adulthood (Ron et al. 1995), it is important 
to evaluate patterns of excess absolute and RRs 
over time. Also, in the view of mild to mod-
erate iodine deficiency in northern Ukraine 
(Ashizawa et al. 1997; Bolshova et al. 1993; 
Tronko et al. 2005), additional data are neces-
sary to clarify the potential modifying effect of 
iodine prophylaxis and/or stable iodine intake 
on I-131–related risk of thyroid cancer (Cardis 
et al. 2005; Shakhtarin et al. 2003).
In the present study, we examined several 
unresolved issues using prospective data from 
a cohort composed of approximately 12,500 
individuals who were < 18 years of age when 
the accident occurred and had individual radio-
activity measurements taken within 2 months 
after the accident (Stezhko et al. 2004). The 
relationship between dose and prevalent thy-
roid cancers diagnosed during the first (base-
line) screening examination (1998–2000) 
has been reported (Tronko et al. 2006a). The 
major objective of the present study was to 
evaluate the dose–response relationship for 
incident thyroid cancers diagnosed as a result 
of second to fourth screening examinations 
based on up to 9 years of follow-up.
Materials and Methods
The cohort. Details of the study design have 
been published previously (Stezhko et al. 
2004; Tronko et al. 2006a). In brief, the 
cohort includes individuals with direct thy-
roid radio  activity measurements made in May 
or June 1986 who were < 18 years of age on 
26 April 1986 and resided in selected areas in 
the neighboring Chernihiv, Zhytomyr, or Kyiv 
oblasts of Ukraine in 1998. An oblast is an 
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Ba c k g r o u n d: Current knowledge about Chornobyl-related thyroid cancer risks comes from 
  ecological studies based on grouped doses, case–control studies, and studies of prevalent cancers.
oB j e c t i v e: To address this limitation, we evaluated the dose–response relationship for incident 
thyroid cancers using measurement-based individual iodine-131 (I-131) thyroid dose estimates in a 
prospective analytic cohort study.
Me t h o d s : The cohort consists of individuals < 18 years of age on 26 April 1986 who resided in 
three contaminated oblasts (states) of Ukraine and underwent up to four thyroid screening exami-
nations between 1998 and 2007 (n = 12,514). Thyroid doses of I-131 were estimated based on 
individual radio  activity measurements taken within 2 months after the accident, environmental 
transport models, and interview data. Excess radiation risks were estimated using Poisson regression 
models.
re s u l t s: Sixty-five incident thyroid cancers were diagnosed during the second through fourth screen-
ings and 73,004 person-years (PY) of observation. The dose–response relationship was consistent 
with linearity on relative and absolute scales, although the excess relative risk (ERR) model described 
data better than did the excess absolute risk (EAR) model. The ERR per gray was 1.91 [95% confi-
dence interval (CI), 0.43–6.34], and the EAR per 104 PY/Gy was 2.21 (95% CI, 0.04–5.78). The 
ERR per gray varied significantly by oblast of residence but not by time since exposure, use of iodine 
prophylaxis, iodine status, sex, age, or tumor size.
co n c l u s i o n s: I-131–related thyroid cancer risks persisted for two decades after exposure, with no 
evidence of decrease during the observation period. The radiation risks, although smaller, are com-
patible with those of retrospective and ecological post-Chornobyl studies.
key w o r d s : Chernobyl nuclear accident; Chornobyl, Ukraine, 1986; dose–response relationship; 
incidence, thyroid neoplasms/epidemiology; iodine; radioactive; radiation. Environ Health Perspect 
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administrative subdivision similar in size to a 
state or province. Of 32,385 individuals origi-
nally selected for the study, 10,307 (31.8%) 
could not be traced primarily because of the 
long interval between the accident and the start 
of screening, as well as high mobility of this 
young cohort; 2,466 (7.6%) were traced but 
were not eligible or available to participate; 
and 6,369 (19.7%) were traced but refused to 
participate or failed to attend the screening, 
resulting in 13,243 (40.9%) individuals who 
were screened for the first time between 1998 
and 2000. After additional exclusions described 
elsewhere (Tronko et al. 2006a), analysis of 
thyroid cancer prevalence was based on 13,127 
individuals. In the present analysis, we also 
excluded 45 individuals who were diagnosed 
with thyroid cancer as the result of the first 
screening examination, 3 individuals who were 
found to have thyroid aplasia, and 566 indi-
viduals (4.3%) who were considered lost to 
follow-up because they participated in only 
the first screening examination. We included 
1 individual who was diagnosed with incident 
thyroid cancer 8 years after the first exami-
nation but was previously excluded from the 
analyses because of incomplete data at baseline. 
This resulted in a total of 12,514 individuals 
included in the present analysis.
The study was reviewed and approved 
by the institutional review boards of the par-
ticipating organizations in Ukraine and the 
United States, and all participants (or their 
legal guardians for those < 16 years of age at 
the time of screening) signed an informed 
consent form.
Screening examination. After a first screen-
ing examination in 1998–2000, three biennial 
thyroid examinations were conducted between 
2001 and May 2007 either by a mobile screen-
ing team or at the Institute of Endocrinology 
and Metabolism (IEM) in Kyiv. Screening 
procedures were standardized and included 
thyroid palpation and ultra  sonographic exami-
nation by a trained ultra  sonographer; indepen-
dent clinical examination and palpation by an 
endocrinologist; a serum sample; a spot urine 
sample; and a series of structured question-
naires eliciting information on demographics, 
medical history, and items relevant to thyroid 
dose estimation, such as residential history, 
milk consumption, and iodine prophylaxis in 
May–June 1986.
Ultrasound examination. Before 2004, the 
thyroid gland was examined using 7.5 MHz 
probes, either an electronic linear transducer 
(Hitachi Medical Systems, Tokyo, Japan; or 
GE Logiq 100, General Electric Company, 
Milwaukee, WI, USA) or a mechanical sector 
probe with water bag kit (Tosbee SSA 240s 
with 7.5 MHz SM-708A probes; Toshiba 
Corp., Tokyo, Japan). Beginning in 2004, this 
equipment was replaced with a laptop-based 
mobile system that used a 10-MHz linear 
probe (Terason Ultrasound, Burlington, MA, 
USA). Details of nodules, echostructure, and 
echogenicity were recorded. The thyroid vol-
ume was calculated based on the volume of an 
ellipsoid as described by Brunn et al. (1981).
Serum assays. Antibodies to thyroid 
peroxi  dase (ATPO), thyroid-stimulating 
hormone (TSH), and thyroglobulin (TG) 
were measured in all available serum samples 
(99% of the cohort) with LUMitest immuno-
chemiluminescence assays (BRAHMS 
Diagnostica GMBH, Heningsdorf, Germany) 
using an AutoLumat LB 953 Luminometer 
(Berthold, Pforzheim, Germany). Based 
on evaluation of reference limits in a refer-
ence sample from our cohort, an eleva-
tion of ATPO > 60 U/mL, consistent with 
BRAHMS, was considered positive. Similarly, 
based on evalua  tion of reference limits in 
a sample from our cohort, reference limits 
of TSH were set between 0.3 mIU/L and 
4.0 mIU/L. According to the manufacturer, 
reference limits of TG measure  ments were 
between 2 ng/mL and 70 ng/mL.
Iodine determination. Urinary iodine con-
tent was measured using the Sandell-Kolthoff 
reaction (Dunn et al. 1993) as described pre-
viously (Tronko et al. 2005).
Thyroid cancer cases. Incident thyroid can-
cers were defined as histologically confirmed 
cancers that were first suspected as a result of 
clinical and laboratory findings during the sec-
ond to fourth screening examinations (2001–
2007) and for which surgery was performed by 
December 2008. All individuals with a nodule 
of ≥ 10 mm in its largest dimension, or a nod-
ule of 5–10 mm with ultra  sound charac  teristics 
suggestive of malignancy (Stezhko et al. 2004), 
were referred for fine-needle aspiration biopsy 
(FNAB) at the IEM. If an individual’s FNAB 
findings were diagnostic or suspicious for 
malignancy or follicular neo  plasia, the person 
was referred for thyroid surgery. Of 855 indi-
viduals referred for FNAB during the second 
to fourth examinations, 637 (75%) complied, 
38 (4%) did not comply, and for 180 (21%) 
the referral was canceled after a repeated ultra-
sound examination. Of the 109 individuals 
referred for thyroid surgery, 87 (80%) com-
plied by December 2008. The International 
Pathology Panel, established in the framework 
of the Chernobyl Tissue Bank (2010), reviewed 
all histopathological diagnoses and confirmed 
all 65 cancers: 61 papillary (with one inciden-
tally found micro  carcinoma), 3 follicular, and 
1 medullary thyroid cancer.
Dosimetry. Dosimetric methods have been 
described elsewhere (Likhtarev et al. 2003, 
2006; Likhtarov et al. 2005). Briefly, indi-
vidual I-131 thyroid doses and their uncer-
tainties were estimated from the combination 
of thyroid radioactivity measurements, data 
on dietary and lifestyle habits, and environ-
mental transfer models using a Monte Carlo 
procedure with 1,000 realizations per indi-
vidual (Likhtarev et al. 2003). The distribu-
tion of 1,000 individual I-131 dose estimates 
was close to lognormal, with geometric SDs 
ranging from 1.6 to 5.0 for most cohort mem-
bers (Likhtarev et al. 2003). For the analysis, 
we used the arithmetic mean of each indi-
vidual’s 1,000 realizations as the best estimate 
of I-131 dose. Because these dose estimates 
were derived from thyroid masses typical of 
iodine-sufficient populations (International 
Commission on Radiological Protection 
1989), we applied a correction coefficient to 
adjust them for thyroid masses typical of the 
Ukrainian population using data collected by 
the Sasakawa Memorial Health Foundation 
(for children 5–16 years of age) (Nikiforova 
et al. 1997) and by the Ukrainian Radiation 
Protection Institute (for children < 5 years 
of age) (Likhtarev IA, personal communica-
tion). In the analysis cohort, the arithmetic 
means [geometric means (GMs)] of individual 
I-131 arithmetic means adjusted for thyroid 
mass typical of this region were 0.65 (0.20) 
Gy compared with the original means of 0.77 
(0.26) Gy, respectively (Tronko et al. 2006a). 
In general, dose estimates were negatively 
correlated with age at time of the accident. 
Individual thyroid dose estimates currently 
are available only for I-131 and not for other 
isotopes of iodine or cesium (Stezhko et al. 
2004). However, I-131 typically accounts for 
90–95% of total thyroid dose (Likhtarev et al. 
2003; Stezhko et al. 2004).
Statistical analysis. We counted person-years 
(PY) at risk from the date of the first screening 
examination to the date of thyroid surgery or to 
the date of last screening examination for those 
not operated upon. Data were cross-classified 
by age at exposure (from 0 to 18 years in 2-year 
intervals), attained age (from 12 to 40 years 
by 2-year intervals), dose estimates (< 0.05, 
0.05–0.09, 0.1–0.29, 0.3–0.49, 0.5–0.69, 
0.7–0.99, 1.0–1.49, 1.5–1.99, 2.0–2.49, 
2.5–2.99, ≥ 3.0 Gy), and calendar time intervals 
(1998–2008 in 1-year intervals).
In addition, data were cross-classified by 
the following categorical variables reflect-
ing status at the time of the first screening 
examination: oblast of residence (Zhytomyr, 
Kyiv, Chernihiv), type of residence (urban/
rural), smoking status (yes/no), family history 
of thyroid disease (yes/no), presence of dif-
fuse goiter on palpation (yes/no), and ultra-
sound-detected nodules (yes/no). Data also 
were cross-classified by sex, oblast of resi  dence 
in 1986 (Zhytomyr, Kyiv, Chernihiv), and 
intake of iodine prophylaxis in May–June 
1986 (yes/no). For each cross-classification 
cell, the number of observed thyroid cancers, 
PY, and PY-weighted means for continuous 
variables at the first screening examination 
(including TSH, ATPO, TG, thyroid vol-
ume, and urinary iodine) were computed.Thyroid cancers in Ukraine after the Chornobyl accident
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We used Poisson regression models for 
grouped survival data to describe thyroid can-
cer incidence rates and to charac  terize radia-
tion effects on these rates under relative and 
absolute risk models. Maximum likelihood 
parameter estimates, likelihood-based confi-
dence intervals (CIs), and tests of indepen-
dence or inter  action were obtained using the 
AMFIT module of Epicure (Preston et al. 
1993). Statistical tests were two sided at an 
α-level of 0.05.
The linear excess relative risk (ERR) model 
has the form r0(x)*(1 + β*dose), where r0 is 
the baseline or background incidence rate, x is 
the vector of covariates that describes the back-
ground rate, and β is the parameter that meas-
ures unit increase in the ERR per gray. The 
linear excess absolute risk (EAR) model has 
the form r0(x) + β*dose, where β is the abso-
lute excess rate of thyroid cancer per gray that 
adds to the background thyroid cancer rate. 
In both ERR and EAR models, background 
rate was modeled as an exponential function 
of sex, oblast of residence at the first screening 
examination, and continuous attained age with-
out inter  action terms. The selected covariates 
were known to be major risk factors for thyroid 
cancer in various populations and/or influenced 
the magnitude of estimated radiation risk in 
preliminary analyses. The ERR and EAR are 
not nested models and cannot be compared 
directly; however, it is reasonable to suggest that 
the fit with lower deviance is the “better” one 
given the same degrees of freedom.
To test departure from linearity, we fitted 
linear-exponential [r0(x)*(1 + β*dose*exp–γ*dose) 
or r0(x) + β*dose*exp–γ*dose)] and linear- 
quadratic [r0(x)*(1 + β*dose + γ*dose2) or r0(x) 
+ β*dose + γ*dose2)] models and compared 
their fit with the simple linear ERR and EAR 
models, respectively. A significant p-value at 
1 degree of freedom (df) of likelihood ratio test 
comparing nested models indicates that the 
data were not consistent with linearity.
To test interaction or departure from the 
constant ERR or EAR models, we fitted the 
dose–response model with main effects only 
and compared its deviance with a model that 
also included dose–response parameters within 
J categories of factor of interest (sex, oblast, 
iodine prophylaxis, and diffuse goiter). A sig-
nificant p-value at J – 1 df indicates that the 
effect of dose is not homogeneous across levels 
of the factor under consideration. Also, for 
continuous variables (age at exposure; attained 
age; time since exposure; and serum TG, 
TSH, and urinary iodine) we evaluated inter-
action with dose based on a 1 df test including 
an interaction term between continuous dose 
and factor under consideration.
Results
Background risk of thyroid cancer. There were 
65 incident thyroid cancer cases and 73,004 
PY of observation in this study. Selected 
associations with background risk of thyroid 
cancer adjusted for I-131 dose based on the 
simple linear ERR models are summarized in 
Table 1. The associations with background 
factors based on the simple linear EAR mod-
els were similar (data not shown). The risk 
increased with attained age (p < 0.001), and 
Characteristic PY (n = 73,004) Cases (n = 65) RR (95% CI)
Sex
Male 35,240 28 1.00 (Referent)a
Female 37,764 37 1.34 (0.82–2.20)
p-Value for homogeneity 0.24
Attained age (years)b
< 22 26,440 16 1.00 (Referent)c
22 to < 30 34,374 25 1.73 (0.90–3.33)
30 to < 40 12,190 24 5.10 (2.60–9.99)
p-Value for homogeneity  < 0.001
Oblast of residenceb
Zhytomyr 20,254d 11 1.00 (Referent)e
Kyiv 14,710 15 2.78 (1.24–6.22)
Chernihiv 37,988 39 4.12 (1.96–8.67)
p-Value for homogeneity  < 0.001
Type of residencyb
Rural 52,690d 43 1.00 (Referent)f
Urban 20,309 22 1.32 (0.76–2.28)
p-Value for homogeneity 0.33
Smoking statusb,g
Nonsmoker 50,718d 44 1.00 (Referent)f
Current smoker 22,279 21 1.12 (0.61–2.06)
p-Value for homogeneity 0.71
Family history of any thyroid diseaseb
No 48,030 46 1.00 (Referent)f
Yes 7,426 7 0.97 (0.43–2.16)
p-Value for homogeneity 0.90
Unknown 17,547 12 0.80 (0.42–1.52)
Thyroid volume (mL)b
< 8.0 16,868 15 1.00 (Referent)f
8.0 to < 12.0 29,795 18 0.61 (0.30–1.22)
12.0 to < 16.0 14,519 13 0.86 (0.40–1.85)
16.0–90.5 11,823 19 1.49 (0.72–3.04)
p-Value for homogeneity 0.06
Diffuse goiterb,h
No 57,122 45 1.00 (Referent)f
Yes 15,882 20 1.55 (0.92–2.63)
p-Value for homogeneity 0.11
Characteristic PY (n = 73,004) Cases (n = 65) RR (95% CI)
Ultrasound-detected noduleb
No 71,335 60 1.00 (Referent)f
Yes 1,669 5 2.44 (0.96–6.19)
p-Value for homogeneity 0.09
Serum TG (ng/mL)b
< 15 30,845 20 1.00 (Referent)f
15.0 to < 24.0 13,642 13 1.41 (0.70–2.84)
24.0 to < 60.0 18,503 17 1.35 (0.70–2.58)
60.0–643.0 4,649 12 3.78 (1.83–7.81)
p-Value for homogeneity 0.01
Unknown 5,363 3 1.42 (0.40–4.97)
Serum TSH (mIU/L)b
< 1.26 18,443 14 1.00 (Referent)f
1.26 to < 1.80 16,684 14 1.13 (0.54–2.37)
1.80 to < 2.70 21,140 17 1.08 (0.53–2.19)
2.70–25.40 16,011 19 1.52 (0.76–3.04)
p-Value for homogeneity 0.60
Unknown 725 1 1.93 (0.25–14.79)
Urinary iodine (μg/L)b
< 25.0 14,317 15 1.00 (Referent)f
25.0 to < 50.0 23,931 23 0.93 (0.48–1.78)
50.0 to < 70.0 12,519 11 0.82 (0.38–1.80)
70.0–750.3 15,634 11 0.63 (0.29–1.38)
p-Value for homogeneity 0.67
Unknown 6,604 5 0.64 (0.23–1.79)
Serum ATPO (U/mL)b
< 10.0 25,165 20 1.00 (Referent)f
10.0 to < 25.0 19,668 17 1.08 (0.57–2.07)
25.0 to < 60.0 18,092 19 1.40 (0.75–2.63)
60.0–18066.0 9,347 8 1.00 (0.44–2.28)
p-Value for homogeneity 0.53
Unknown 732 1 1.82 (0.24–13.63)
aAdjusted for attained age, oblast, and I-131 dose. b Reported at interview or detected during the first screening examination. cAdjusted for sex, oblast, and I-131 dose. dPYs do not add 
up to column total due to missing values (data not shown because they do not contain cancer cases). eAdjusted for sex, attained age, and I-131 dose. fAdjusted for sex, attained age, 
oblast, and I-131 dose. gData did not allow separation of never-smokers and former smokers, so these were grouped together in one category of non  smokers. hBased on palpation by 
endocrinologist and defined as grade 0, 1, or 2. In the analysis, grades 1 and 2 were combined as the “yes” category. 
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the magnitude of this increase appeared 
similar in males and females (p interac-
tion = 0.27; data not shown). Risk of thy-
roid cancer was four times higher in residents 
of Chernihiv oblast and > 2.5 times higher 
in residents of Kyiv oblast than in residents 
of Zhytomyr oblast at the first screening 
examination (p < 0.001). Also, larger thyroid 
volume (p = 0.06), presence of diffuse goi-
ter (p = 0.11), ultrasound-detected nodules 
(p = 0.09), and elevated levels of serum TG 
(p = 0.01) at the first screening examination 
appeared to be associated with increased risk 
of thyroid cancer.
Dose response with I-131. To evaluate the 
dose–response relationship with I-131, we fit-
ted both linear ERR and EAR models. The 
estimated radiation risks were 1.91 (95% CI, 
0.43–6.34; p < 0.001) for ERR per gray and 
2.21 × 10–4 PY per gray (95% CI, 0.04 × 10–4 
to 5.78 × 10–4; p = 0.02) for EAR, demon-
strating a strong association with I-131 expo-
sure for incident thyroid cancer. As evidenced 
from the models’ deviance, the linear ERR 
model appeared to describe our data better 
than did the linear EAR model (1001.799 
vs. 1012.589, respectively). The I-131 dose-
category–specific RRs and fitted RRs based on 
the simple linear ERR model are presented in 
Figure 1. The linear dose–response model pro-
vided an adequate fit to the categorical RRs. 
Inclusion of neither a linear-exponential (LE) 
nor a linear-quadratic (LQ) term significantly 
improved the fit compared with simple linear 
ERR (pLE = 0.16 and pLQ = 0.31) or linear 
EAR models (pLE = 0.13 and pLQ = 0.33).
When we repeated dose–response analyses 
for only papillary thyroid cancers (n = 61), the 
ERR per gray was 1.58 (95% CI, 0.30–5.44; 
p < 0.001) and the EAR per 104 PY per gray 
was 1.71 (95% CI, < 0.06–4.95; p = 0.03). 
Exclusion of one incidentally found papillary 
thyroid microcarcinoma had no effect on either 
estimate of radiation risk (data not shown).
Modification of the I-131 dose response. 
The ERRs according to categories of selected 
factors are summarized in Table 2. The 
ERR per gray was higher for residents of 
Kyiv oblast and particularly of Chernihiv 
oblast than for residents of Zhytomyr oblast 
at the first screening examination (p inter-
action = 0.008). Similarly, the EAR in 
Kyiv was 5.78 (95% CI, 0.39–16.38), in 
Figure 1. Dose–response relationship between inci-
dent thyroid cancers and I-131 dose estimates in 
a cohort study of thyroid cancer and other thyroid 
diseases after the Chornobyl accident in Ukraine. 
The solid line represents fitted RRs based on the lin-
ear ERR model; data points and error bars represent 
  category-specific RRs and 95% CIs for mean I-131 
dose per category. The fitted linear dose response 
was adjusted to pass through the lowest I-131 
category. The ERR was adjusted for sex, oblast of 
residence at the first screening examination, and 
continuous attained age.
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Table 2. Effect modification of the ERR of incident thyroid cancer per gray of exposure according to 
selected characteristics.
Characteristic PY (n = 73,004) Cases (n = 65) ERR per gray (95% CI)
Sex
Male 35,240 28 1.20 (0.03 to 6.74)a
Female 37,764 37 2.66 (0.46 to 12.49)
p-Valueb 0.40
Age at exposure (years)
0 to < 4 21,236 18 7.43 (< 1.67 to NE)c
4 to < 12 34,941 31 1.57 (–0.02 to 8.51)
12 to < 18 16,827 16 0.69 (< –0.04 to 6.31)
p-Value 0.40
Attained age (years)
< 22 26,440 16 2.08 (0.10 to > 13.65)d
22 to < 30 34,374 25 1.83 (0.01 to 11.97)
30 to < 40 12,190 24 0.74 (< 0.06 to 4.95)
p-Value 0.71
Time since exposure (years)e
< 16.7 1,209 21 2.85 (0.08 to 44.31)c
16.7 to < 20.0 40,385 24 1.31 (0.05 to 7.18)
20.0–22.4 31,409 20 3.69 (0.43 to 42.80)
p-Value 0.60
Oblast of residencef
Zhytomyr 20,254g 11 0.06 (< –0.02 to 1.08)h
Kyiv 14,710 15 2.70 (0.27 to 27.52)
Chernihiv 37,988 39 4.07 (0.95 to 16.80)
p-Value 0.008
Oblast of residence in 1986f
Zhytomyr 20,816 12 0.08 (< –0.01 to 1.27)h
Kyiv 13,443 11 1.22 (–0.02 to 12.59)
Chernihiv 38,746 42 5.20 (1.45 to 21.40)
p-Value 0.005
Iodine prophylaxis in May–June 1986f
No 51,674g 50g 2.11 (0.36 to 9.28)c
Yes 18,154 12 1.03 (< 0.08 to 9.84)
p-Value 0.56
Diffuse goiterf,i
No 57,122 45 1.78 (0.33 to 6.41)c
Yes 15,882 20 2.07 (0.03 to > 28.4)
p-Value 0.89
Serum TG (ng/mL)f
< 15.0 30,845g 20g 1.58 (< 0.32 to 13.77)c
15.0 to < 31.0 20,687 21 1.89 (0.18 to 12.21)
31.0–643.0 16,108 21 2.58 (0.16 to 34.73)
p-Value 0.92
Serum TSH (mIU/L)f
< 1.3 17,265g 14g 2.61 (0.06 to 30.89)c
1.3 to < 2.5 33,750 28 1.97 (0.06 to 12.30)
2.5–25.4 19,448 21 1.05 (0.02 to 7.60)
p-Value 0.74
Urinary iodine (μg/L)f
< 34.0 22,674g 20g 0.60 (< –0.002 to 5.69)c
34.0 to < 50.0 15,573 18 3.72 (0.36 to 52.48)
50.0–750.3 28,153 22 2.23 (0.16 to 18.49)
p-Value 0.36
NE, not estimable.
aAdjusted for attained age and oblast. bp-Value for tests of homogeneity of linear trends across categories of interest or 
1 df interaction test between dose and continuous variable. cAdjusted for sex, attained age, and oblast. dAdjusted for sex, 
oblast, and time since exposure. eDifference between the exit date (date of thyroid surgery or last screening examina-
tion for those not operated upon) and date of the accident. fReported at interview or detected during the first screening 
examination. gPerson-years or cancer cases may not add up to column total because of missing values (excluded from 
analyses). hAdjusted for sex and attained age. iBased on palpation by endocrinologist and defined as grade 0, 1, or 2. In 
the analysis, grades 1 and 2 were combined as the “yes” category. Thyroid cancers in Ukraine after the Chornobyl accident
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Chernihiv 16.56 (95% CI, 7.83–27.92), and 
in Zhytomyr 0.37 (95% CI, < 0.01 to 2.27) 
per 104 PY per gray (p inter  action < 0.001). 
We observed the same pattern of radiation 
risks for place of residence in 1986 (p inter-
action for ERR = 0.005; p interaction for 
EAR < 0.001). The EAR, but not ERR per 
gray, varied significantly according to attained 
age, with older individuals having higher 
EARs (p inter  action < 0.001). Specifically, 
EAR (per 104 PY per gray) was 0.90 (95% 
CI, < 0.02–3.41) in individuals < 22 years of 
age; 5.25 (95% CI, 1.57–11.38), in 22- to 
< 30-year-olds; 5.25 (95% CI: 1.57–11.38), 
and 20.5 (95% CI, 6.24–42.08) in individu-
als ≥ 30 years of age. Although neither ERR 
nor EAR per gray varied significantly by other 
charac  teristics, some patterns are notewor-
thy. Specifically, the ERR per gray tended 
to increase with decreasing age at exposure 
and to be higher in females than in males; 
it was elevated throughout the observation 
period and did not vary meaningfully by time 
since exposure; and ERR per gray was some-
what higher for those who did not take iodine 
prophylaxis in 1986 or had diffuse goiter or 
higher levels of serum TG at the first screen-
ing examination. We observed no consistent 
pattern in radiation risk according to urinary 
iodine concentration or serum TSH at the 
first screening examination.
Additional dose–response analyses accord-
ing to pathomorphological size of the carcinoma 
categorized < 10 mm (n = 31) or ≥ 10 mm 
(n = 34) revealed a higher ERR per gray for 
the larger cancers (2.56; 95% CI, 0.46–11.26; 
p < 0.001) versus the smaller ones (0.90; 95% 
CI, < 0.05 to 8.00; p = 0.05), but this difference 
was not statistically significant (p = 0.97).
Discussion
In this prospective cohort study of individuals 
exposed as children or adolescents to fallout 
from the Chornobyl accident, we found a sig-
nificant dose–response relationship between 
individual I-131 thyroid dose estimates and 
risk of incident thyroid cancer 15–22 years 
after the accident. Like cohort studies of 
externally irradiated populations (Ron et al. 
1995), our study found that the ERR model 
described the data better than the EAR 
model, and both models were consistent with 
linearity over the entire range of doses. The 
estimated ERR for incident thyroid cancer 
per gray was 1.91 (95% CI, 0.43–6.34), and 
the EAR was 2.21 × 10–4 PY per gray (95% 
CI, 0.04 × 10–4 to 5.78 × 10–4). The estimate 
of ERR per gray for incident thyroid cancer, 
although smaller, is compatible with the esti-
mate of excess odds ratio per gray for preva-
lent thyroid cancer previously reported in this 
cohort (5.25; 95% CI, 1.70–27.5) (Tronko 
et al. 2006a) and in other case–control stud-
ies of post-Chornobyl thyroid cancer (Cardis 
et al. 2005; Davis et al. 2004). Similarly, the 
estimate of EAR in our cohort is compa-
rable to the EARs observed in several post- 
Chornobyl ecological studies (Jacob et al. 
1999, 2006; Likhtarov et al. 2006). The radi-
ation risks from our study also could be com-
pared with the risks from gamma rays and 
X rays reported in the pooled analysis of irra-
diated populations [ERR per gray = 7.7 (95% 
CI, 2.1–28.7) and EAR/104 PY per gray = 4.4 
(95% CI, 1.9–10.1), respectively] (Ron et al. 
1995). Although the estimates from our study 
are lower than the respective estimates for 
gamma rays and X rays, some uncertainty 
remains in these comparisons because of wide 
CIs and lack of adjustment for age at expo-
sure and other important confounders and/or 
effect modifiers.
Our results suggest that thyroid cancers 
attributable to I-131 exposure continue to 
occur two decades after exposure, with papil-
lary thyroid cancer remaining the main his-
tological type (94%). There is no indication 
of diminishing ERR per gray with increasing 
time since exposure within the narrow range 
of the available observation period. In a pooled 
analysis of thyroid cancer studies after exter-
nal irradiation, excess risk peaked 15–19 years 
after exposure and then declined, although an 
excess was still apparent 40 years later (Ron 
et al. 1995). If studies of external radiation can 
serve as a guide, continued follow-up of this 
cohort is necessary to more accurately describe 
the pattern of radiation risks over time.
We found that the EAR, but not ERR per 
gray, increased with attained age, a finding 
that is likely to be related to increase in back-
ground rates of cancer with increasing age. 
One of the most consistent findings for thy-
roid cancer after external irradiation is a trend 
for increasing ERR per gray with younger age 
at exposure (Ron et al. 1995). This was also 
reported in previous studies of thyroid can-
cer after the Chornobyl accident (Jacob et al. 
1999, 2006; Likhtarov et al. 2006; Tronko 
et al. 2006a). In the present study we demon-
strated that the ERR per gray for 0 to < 4 years 
of age at exposure (7.43) was > 10 times that 
for 12 to < 18 years of age at exposure (0.69) 
(Table 2), although the trend was not statisti-
cally significant. In contrast to age at exposure, 
the variation of radiation risk by sex has been 
inconsistent (Cardis et al. 2005; Jacob et al. 
1999, 2006; Likhtarov et al. 2006; Ron et al. 
1995). In our data, the ERR and EAR per 
gray were higher in females, but the differ-
ences between males and females were not 
statistically significant.
Although the modification of I-131–related 
thyroid cancer risk by iodine prophylaxis or 
intake of stable iodine is important in view 
of the mild to moderate iodine deficiency 
prevailing in northern Ukraine (Nikiforova 
et al. 1997; Robbins et al. 2001; Tronko et al. 
2005), it is difficult to study because data on 
iodine status at the time of the accident, the 
most relevant time period, are not readily avail-
able. In the only other analytical study that 
attempted to address this question, Cardis et al. 
(2005) found that self-reported intake of iodine 
prophylaxis was associated with lower risk of 
I-131–related thyroid cancer and that residence 
within iodine-deficient territories at the time 
of the accident was associated with higher risk 
of I-131–related thyroid cancer independent 
from each other. In the present study, individ-
uals who reported intake of iodine prophylaxis 
had somewhat lower ERR per gray, although 
the difference was not statistically significant. 
Using a variety of indicators of stable iodine 
intake at the time of the first screening exami-
nation (i.e. 12–14 years after the accident), we 
found that the I-131–related risks tended to be 
higher among individuals with diffuse goiter 
or with higher levels of serum TG, but not in 
individuals with lower concentration of urinary 
iodine. Taken together, our data are not strong 
enough to support a modifying effect of either 
iodine prophylaxis or iodine deficiency on 
I-131–related risk of thyroid cancer, although 
our power to detect interactions was limited.
We found that background risk and 
I-131 excess risks exhibited significant varia-
tion according to oblast of residence at the 
first screening examination, with individuals 
from Chernihiv oblast, and to a lesser extent 
from Kyiv oblast, having higher risks than 
individuals from Zhytomyr oblast. Analyses 
using oblast of residence at the time of the 
accident provided similar results, reflect-
ing the strong correlation between the two 
residences in time. Because screening of the 
cohort was conducted according to a standard-
ized protocol and no meaningful differences 
were observed in compliance rates with FNAB 
or thyroid surgery by oblast, case ascertain-
ment was unlikely to have caused a geographic 
difference. Interestingly, analyses of other 
thyroid outcomes in this cohort, including fol-
licular adenoma (Zablotska et al. 2007), hypo-
thyroidism (Ostroumova et al. 2009), and 
autoimmune-related outcomes (Tronko et al. 
2006b), demonstrated that oblast of residence 
was also associated with background risk for 
these outcomes, suggesting a Zhytomyr–Kyiv–
Chernihiv gradient. Thus, although three 
oblasts are generally similar in socio  economic 
status and ethnicity, we cannot rule out a pos-
sibility that the oblast of residence may be 
a surrogate indicator for some unmeas  ured 
effect modifier. If oblast of residence was a 
surrogate marker for iodine deficiency status 
at the time of the accident and residents of 
Chernihiv oblast experienced stronger iodine 
deficiency in 1986 than did residents of 
Kyiv and Zhytomyr oblasts, this could have 
explained the observed pattern. Unfortunately, 
data concerning iodine status in the study areas Brenner et al.
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in 1986 are not available, and 1991 data from 
the Sasakawa group (Nikiforova et al. 1997) 
are consistent with our data from 1998–2000 
(Tronko et al. 2005) in that Zhytomyr oblast, 
but not Chernihiv oblast, appears generally 
more iodine deficient. Although we can-
not explain the regional hetero  geneity in the 
cohort, this does not change the fact that there 
clearly is a strong dose–response relation with 
I-131 exposure in the cohort.
One of the unresolved issues in studies of 
thyroid cancer after radiation exposure is the 
effect of screening on radiation risk estimates. 
Because everyone in our cohort was screened 
regardless of dose, confounding by screening 
intensity is unlikely. However, it remains con-
troversial whether the detection of additional 
small thyroid cancers, which in the absence 
of thyroid screening might only have been 
detected later, would affect the excess radiation 
risks, as well as whether these small tumors 
are induced by radiation to the same extent as 
large tumors. The ERR per gray in the Michael 
Reese Hospital cohort of children externally 
irradiated for enlarged tonsils and adenoids 
was not significantly different before and after 
1974, when the radiation issue became recog-
nized and a screening program was initiated 
(Schneider et al. 1993). Similarly, in atomic 
bomb survivors Akiba et al. (1991) observed no 
significant difference in ERR per gray between 
those who were part of a periodically screened 
cohort and those who were not. Because the 
ERR appears to be unaffected by screening and 
represents a ratio of excess radiation cancers to 
background cancers, this implies that screen-
ing proportionally increases background and 
excess radiation cancers with small tumors and, 
therefore, that some of the small tumors are 
radiation related. In our cohort, direct evalua-
tion of the dose response according to tumor 
size showed that, although the ERR per gray 
for cancers ≥ 10 mm was approximately three 
times larger than that for cancers < 10 mm, 
the ERR per gray for the small cancers was 
also elevated and the ERRs in both groups 
were not statistically different. The only other 
empirical data available on dose response by 
thyroid tumor size is from the cohort of atomic 
bomb survivors, in which radiation effects for 
small papillary carcinomas identified at autopsy 
were found (Hayashi et al. 2010; Sampson 
et al. 1969; Yoshimoto et al. 1995). Taken 
together, current evidence suggests that both 
small and large thyroid tumors are related to 
radiation exposure, yet additional data are nec-
essary to determine if the magnitude of the 
dose response differs.
Although the main focus of our analysis 
was on quantification of I-131–related risk of 
incident thyroid cancer, our study also pro-
vides data on the epidemiology of thyroid 
cancer in general. Our findings of increased 
background risk of thyroid cancer among 
persons diagnosed with diffuse goiter or ultra-
sound-detected nodules at the first screening 
examination are consistent with findings from 
a pooled analysis of case–control studies of 
thyroid cancer in which a self-reported his-
tory of benign thyroid diseases was a signif-
icant thyroid cancer risk factor (Franceschi 
et al. 1999). Another interesting finding in 
our cohort was that the risk of thyroid cancer 
was approximately four times higher in those 
with serum levels of TG > 60 ng/mL com-
pared with those with TG < 15 ng/mL. This 
association persisted after adjustment for pres-
ence of diffuse goiter or ultrasound-detected 
nodules at the first screening examination and 
is consistent with a previous report suggesting 
that serum TG, in addition to its established 
link with iodine deficiency, may be an early 
marker of thyroid cancer risk (Hrafnkelsson 
et al. 2000).
Among the major strengths of our study 
are its prospective nature, availability of indi-
vidual I-131 dose estimates derived from radio-
activity measure  ments taken within 2 months 
after the accident, low losses to follow-up 
(4.3%), near complete ascertainment of cases 
due to standardized screening examination, 
high rates of compliance with FNAB (75%) 
and surgery (80%), and review of pathologi-
cal slides by an international panel of experts. 
A study limitation is the low statistical power 
to evaluate effect modification because of the 
small number of cases and the relatively short 
follow-up. We do not believe that the results 
of our study could be attributed to selection 
bias, even though during the first screening 
cycle we examined 40.9% of those originally 
selected for tracing or 67.5% of those located 
and invited to participate, because distribu-
tion of measured thyroid radioactivity was 
similar among participants (n = 13,243) and 
non  participants (n = 19,142) (Stezhko et al. 
2004). The impact of uncertainties in dose 
estimates, 95% of which are typically attrib-
utable to unknown thyroid gland mass and 
the I-131 content in thyroid gland in 1986 
(Likhtarev et al. 2003), was not taken into 
account. Because the error for thyroid mass is 
likely to be a mixture of classical error (which 
arises from an imprecise measuring device) 
and Berkson error (which arises when a single 
measurement is used to represent a group of 
subjects with varying true values), and because 
the error for direct thyroid measurement 
is largely classical, our study should have a 
mixed error structure. In a study of thyroid 
disease related to radiation fallout from the 
Nevada test site, Mallick et al. (2002) found 
that when a mixture error model was used 
to account for measure  ment error, radiation 
risk estimates were higher than unadjusted 
estimates, but < 100% higher than when all 
error was assumed to be classical. Based on 
these results, it seems reasonable to assume 
that the true radiation risk for incident thyroid 
cancer is likely to be higher than what we have 
reported, although with greater uncertainty.
Conclusions
We found a significant linear dose–response 
relationship between individual I-131 thy-
roid dose estimates and risk of incident thy-
roid cancer two decades after the Chornobyl 
accident. The excess radiation risks, although 
somewhat smaller, were compatible with those 
of retrospective and ecological post-Chornobyl 
studies and studies of external irradiation and 
suggest that risk has not disappeared over time. 
However, additional follow-up of this cohort 
is necessary to more accurately describe the 
excess radiation risks by time since exposure 
and other factors.
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